Clinical trials
Fibrosis clinical trials
Below are recruiting fibrosis clinical trials, each written for real people, not researchers. We’re tracking 437 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT00373841Recruiting
Study of genetic and protein changes in idiopathic pulmonary fibrosis
This study looks at genetic (DNA) and protein changes over time in people with idiopathic pulmonary fibrosis, to better understand how the disease progresses. Your participation may help researchers learn patterns that could guide future care.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT00258570Recruiting
Study genetics in idiopathic pulmonary fibrosis patients
This study looks at genetic differences in people with idiopathic pulmonary fibrosis (a lung scarring condition with no known cause). It may help researchers understand what influences the disease and guide future treatment options.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT00001532Recruiting
How Genes Affect Lung Disease Development
This research study examines how genetic factors contribute to various lung diseases, including alpha-1 antitrypsin deficiency, cystic fibrosis, and chronic obstructive pulmonary disease. Researchers want to understand why some people develop lung disease and how genetics plays a role, which may help improve treatment in the future.
Bethesda, MarylandAges 2–90 - NCT01852448Recruiting
Study genes affecting insulin in people with cystic fibrosis
This study looks at how genes may affect insulin and “incretin” hormones in people with cystic fibrosis. It may help researchers understand why some people develop blood-sugar problems and how to predict or prevent them.
Philadelphia, PennsylvaniaAges 2 years+ - NCT00515567Recruiting
Study lung tissue from people with lung scarring
This study uses lung tissue removed during lung transplant to learn more about lung scarring (pulmonary fibrosis). It can help researchers understand the disease better and improve future treatments.
Chicago, IllinoisAges 18 years+ - NCT01851694Recruiting
Study incretin hormone response in adults with cystic fibrosis
This study tests how the body’s “incretin” hormones affect insulin (sugar control) in adults with cystic fibrosis and certain blood sugar patterns. It may help explain what drives diabetes risk in cystic fibrosis and how the body responds to these hormone signals.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02206841Recruiting
Study to confirm fatty liver and build fibrosis test markers
This study enrolls people with confirmed fatty liver to help researchers create and validate tests that may estimate liver scarring (fibrosis). It focuses on collecting medical information and verifying the liver condition using lab/scan results, which could help improve future care.
SeoulAges 18 years+ - NCT02270476Recruiting
Study of how cystic fibrosis lung disease changes over time
This observational study follows children newly diagnosed with cystic fibrosis to understand how their lung disease develops. It may help doctors better predict disease course and choose the right timing for care.
Heidelberg, Baden-WurttembergAges Any age - NCT02417740Recruiting
Study of the natural course of noncirrhotic portal hypertension
This study follows people with noncirrhotic portal hypertension (NCPH) or people at risk for it to better understand how the condition progresses over time. It does not sound like a medication trial—more like careful monitoring to learn what happens in different people.
Bethesda, MarylandAges 12–100 - NCT05699018Recruiting
Screening people with liver scarring in primary care
This study tests how well primary care doctors can screen for advanced liver scarring in people with fatty liver from non-alcohol causes or from alcohol use. It may help find liver problems earlier so you can get the right follow-up.
AngersAges 40–80 - NCT06488638Recruiting
Beetroot juice supplement for lung fibrosis
This trial tests whether a beetroot juice drink (rich in nitrates) can help people with idiopathic pulmonary fibrosis breathe better and exercise more. It's a small pilot study to see if it's safe and worth studying further.
SouthamptonAges 18–85 - NCT01113216Enrolling by invitation
Genetics study for diabetes in cystic fibrosis families
This study looks at genetic (inherited DNA) factors that may influence who develops diabetes related to cystic fibrosis. Your results could help doctors better predict risk and improve care for cystic fibrosis and related diabetes.
Chicago, IllinoisAges 3 months–99 years - NCT07447102RecruitingPhase 2
Study of BC006 for Idiopathic Pulmonary Fibrosis
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT07449000Recruiting
Losartan for corneal scar treatment
This trial tests if losartan, a common blood pressure medicine, can help reduce corneal scars. It may be an option for adults with a stable corneal scar that has been present for at least one month.
Monterrey, Nueo LeonAges 18 years+ - NCT07457463Recruiting
Pulmonary fibrosis self-management program
This study tests a learning and self-management program for people with pulmonary fibrosis. It helps you better understand and manage your lung condition.
BernAges 18 years+ - NCT07464912RecruitingPhase 3
Testing TDI01 for idiopathic pulmonary fibrosis
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
Beijing, Beijing MunicipalityAges 40–80 - NCT07466420Recruiting
Quercetin for fibrotic lung disease
This trial tests whether taking quercetin, a natural supplement, can help people with fibrotic interstitial lung diseases (a group of conditions that cause scarring in the lungs). If you have been diagnosed with idiopathic pulmonary fibrosis (IPF) or another fibrotic ILD and are on standard treatments, you may be able to join.
Heraklion, CreteAges 18 years+ - NCT07486206Recruiting
Optimizing follow-up for interstitial lung disease
This trial tests a new way to organize follow-up visits for people with interstitial lung disease (a group of lung conditions). It aims to make care simpler and more effective for patients who are already on treatment.
Granollers, BarcelonaAges 18 years+ - NCT07508904Recruiting
Exercise effects in children with cystic fibrosis
This study tests whether a specific exercise program can improve muscle strength, breathing, and fitness in children with cystic fibrosis who are stable and able to exercise.
LahoreAges 6–18 - NCT07569419RecruitingEarly Phase 1
Testing Linaclotide for Cystic Fibrosis Bowel Function
This early-stage study tests whether a medication called linaclotide can help improve bowel function in people with cystic fibrosis. Researchers will use MRI scans and other tests to see how the medication affects your digestive system.
NottinghamAges 18–65 - NCT07588854Recruiting
Liver Stiffness Testing and Biopsy for Chronic Liver Disease
This study compares two non-invasive ultrasound methods (EUS-SWQ and FibroScan) with liver biopsy to see how well they detect liver scarring in patients with chronic liver disease. The goal is to improve how doctors diagnose and monitor liver damage from conditions like hepatitis B and fatty liver disease.
ShanghaiAges 18–80 - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+ - NCT07629986Recruiting
How antibiotics work in cystic fibrosis patients on ETI therapy
This study measures how antibiotics are processed by the body in people with cystic fibrosis who are taking a combination drug called elexacaftor/tezacaftor/ivacaftor (ETI). Understanding this helps doctors prescribe the right antibiotic doses for patients on this newer treatment.
RoscoffAges 12 years+ - NCT07658755Recruiting
LiverSeek: Finding advanced liver scarring in MASLD
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
Madrid, MadridAges 50–75
Hear when a new Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fibrosis?
- Yes. Clin2 currently lists 437 recruiting fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.